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Effect of non-nicotinic moist snuff replacement and
lobeline on withdrawal symptoms during 48-h
smokeless tobacco deprivation
Dennis E. McChargue, Frank L. Collins, Jr., Lee M. Cohen
[Received 20 November 2000; accepted 2 March 2001]
The present study investigated the effects of two herbal components (BACCOFF™ and DIPSTOP™) of a
commercially available smokeless tobacco treatment program for reducing subjective withdrawal symptoms
during deprivation. One component, BACCOFF™, is a non-nicotinic chew. The second component,
DIPSTOP™, is a liquid containing the alkaloid lobeline, which to some extent mimics peripheral nicotinic
effects. All participants ( N = 22 males) were placed in four conditions: BACCOFF™ + DIPSTOP™,
BACCOFF™ + placebo control, DIPSTOP™ only, and placebo control only. The conditions involved 48 h of
deprivation, and subjects were exposed to one condition per week for 4 weeks. Withdrawal measures were taken
at baseline, 24 h, and 48 h of deprivation. Individuals were randomly assigned, and conditions were
counterbalanced. Results showed that BACCOFF™, as compared with DIPSTOP™, significantly reduced
withdrawal symptoms but not craving. These data suggest that behavioral/sensory substitutes’ influence on
withdrawal might be routed through the product’s ability to approximate the preferred moist snuff.

Introduction
Smokeless tobacco consumption in the USA, particularly
among moist snuff users, has been on the rise over the
past three decades, while the consumption of other
nicotine products has progressively decreased ( USDA,
1993; USDHHS, 1996). Although white males between
the ages of 18 and 35 tend to report the highest rates of
daily smokeless tobacco use ( USDHHS, 1996), other
epidemiological evidence suggests that greater numbers
of male adolescents and children, often under the age of
12, are experimenting with and progressing toward using
smokeless tobacco on a regular basis ( Hill, Harrell, &
McCormick, 1992; Simon, Sussman, Dent, Burton, &
Flay, 1993). The extent to which smokeless tobacco use
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produces physical dependence via frequent and prolonged nicotine exposure ( West, 1988 ) may increase the
likelihood that these young smokeless tobacco users will
become highly dependent on nicotine much earlier and
that they may have more difficulty initiating and
maintaining abstinence. Moreover, greater health risks
associated with regular smokeless tobacco use, which
include periodontal problems, soft tissue alterations/
leukoplakia, and cancers of the oral cavity and pharynx
( see Hatsukami & Severson, 1999), highlight the importance of examining factors that aid our understanding of
smokeless tobacco use, maintenance, and eventual
cessation.
One plausible mechanism that may contribute to the
entrenched consumption patterns of young, dependent
smokeless tobacco users is the level of nicotine withdrawal such people experience when they attempt to
abstain from use. Insofar as aversive withdrawal symptoms promote relapse and the anticipation of aversive
symptoms reduces the motivation to attempt to quit,
elevated nicotine withdrawal symptoms, especially during the first 48 h of abstinence, may hinder smokeless
tobacco users’ efforts to maintain abstinence. Nicotine
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withdrawal severity as it pertains to implications for
future smokeless tobacco treatment is an area that is
not well understood. Cigarette smokers and smokeless
users show similar signs and symptoms of nicotine
withdrawal ( Hatsukami, Gust, & Keenan, 1987;
McChargue & Collins, 1998) and report comparable
withdrawal severity ratings within the first 48 h of
nicotine abstinence ( McChargue & Collins, 1998). As
such, it may be reasonable to suggest that severe
nicotine withdrawal symptoms may also place smokeless tobacco users at a heightened risk for relapse.
Moreover, our ability to abate unpleasant nicotine
withdrawal symptoms may substantially help a person
to resist the urge to return to using smokeless tobacco
following abstinence.
To our knowledge, no study has tested the hypothesis
that elevated nicotine withdrawal symptoms predict
smokeless tobacco relapse. At best, previous research has
shown that nicotine replacement treatments ( NRT)
alleviate withdrawal symptoms in most studies ( Hatsukami, Anton, Keenan, & Callies, 1992; Hatsukami et al.,
2000 ) but not all ( Hatsukami, Jensen, Allen, Grillo, &
Bliss, 1996). Although Hatsukami and colleagues
showed that NRT significantly enhanced rates of abstinence at 6 months ( point-prevalence abstinence) and up
to 15 weeks (continuous abstinence), it remains unclear
whether NRT effectiveness was a result of the lowering
of withdrawal symptoms.
There is some evidence to suggest that non-nicotinic
products reduce nicotine withdrawal symptoms. In
particular, citric and ascorbic acid devices ( Levin et al.,
1993 ), and de-nicotinized cigarettes (Butschky, Bailey,
Henningfield, & Pickworth, 1995) have been used as
sensory substitutes. Previous studies have shown that
smokers report comparable satisfaction ratings for sensory substitutes as compared with cigarettes ( Rose &
Hickman, 1987), as well as report lower nicotine
withdrawal symptoms, including craving, during abstinence ( Behm et al., 1993; Butschky et al., 1995; Levin et
al., 1993 ). Although there are some data to suggest
sensory substitutes may aid in smoking cessation ( e.g.,
Levin et al., 1993 ), such evidence is very preliminary
and in need for further research.
Less is known about the effects of non-nicotinic
replacements that approximate behaviors and sensations
of smokeless tobacco. Three studies currently report the
use of behavioral/sensory replacements ( e.g., mint-leaf
snuff) in smokeless tobacco treatment. For example,
when a quit kit of oral substitutes such as chewing gum,
toothpicks, and a tin of ground mint-leaf non-tobacco
snuff was given as a part of a smokeless tobacco
intervention, Stevens, Severson, Lichtenstein, Little, and
Leben ( 1995 ) found that the use of oral replacements
were significant predictors of quitting at 3- and 12-month
follow-up. Zavala, Harrison, Smith, Smith, and Manske
( 1995 ) also reported that use of mint snuff was highly
associated with more days tobacco-free. Despite the
promise that mint snuff may help prolong abstinence, it
has been difficult to determine whether the increased

abstinence rates were a direct result of the use of
behavioral/sensory replacements. More recently, Hatsukami et al. (2000) conducted a study that examined the
effectiveness of mint snuff and transdermal nicotine
patch to aid in smokeless tobacco abstinence. Participants were only blinded to the patch condition ( active vs.
placebo), whereas they either received or did not receive
the mint snuff. Although mint snuff users reported lower
levels of withdrawal symptoms ( i.e., craving, irritability/
frustration/anger, anxiety, and depressed mood) during
nicotine abstinence, the use of mint snuff did not affect
abstinence rates.
If non-nicotinic replacement treatments encourage
nicotine abstinence through potential withdrawal-alleviating effects, despite some initial evidence to the
contrary ( Hatsukami et al., 2000 ), a better understanding
of factors that may influence the magnitude of withdrawal reduction while prolonging abstinence rates
would help resolve some inconsistent findings reported
in previous research. The present study attempted to
further evaluate the effects of non-nicotine replacements
on nicotine withdrawal symptoms of moist snuff users.
We aimed to test the hypothesis that two commercially
produced non-nicotine replacements ( herbal snuff and
liquid lobeline by Ralston, Inc.) would substantially
reduce withdrawal symptoms during 48 h of nicotine
deprivation. Insofar as such non-nicotinic replacements
represent alternative reinforcers that approximate the
properties and effects of moist snuff, the more effective
they might be at reducing negative consequences associated with nicotine abstinence. In other words, we
expected the replacement products that were reported to
produce the closest behavioral, sensory, and physiological responses to moist snuff during 48-h deprivation
would also greatly mitigate signs and symptoms of
nicotine withdrawal.
Method
Participants
Male moist snuff users ( N = 22) were recruited from
undergraduate introductory psychology courses at Oklahoma State University and were given extra credit for
their participation. Three participants did not complete
the protocol. There were no significant demographic
differences for people who did not complete the study. A
lottery for $100 was also conducted at the end of each
semester. Participants completing the entire protocol
were eligible for the lottery as an extra incentive.
Participants had a mean ( ±SD) age of 19.81±1.87
years and a Smokeless Tobacco Dependence Questionnaire ( SMTDQ, described more fully later) score of
7.94±3.0. Smokeless tobacco users consumed more than
two tins per week ( 11 participants consumed more than
four tins per week) and had at least 2 years of continuous
moist snuff usage without currently using any other form
of nicotine product or attempting to quit or cut down on
smokeless tobacco consumption.
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Materials
Compliance measures. The primary compliance measures were self-reported nicotine abstinence and selfreported product usage at 24- and 48-h nicotine deprivation. Previous research has shown that the expectation of
biochemical verification of tobacco use produces more
accurate self-reports than without the threat of biochemical verification ( Hansen, Malotte, & Fielding,
1985; Murray, O’Connell, Schmid, & Perry, 1987). Thus,
saliva samples were collected and individuals were
informed that the saliva samples would be used to assess
systemic nicotine levels from smokeless tobacco use. No
physiological or pharmacological indices were derived
from the samples. Furthermore, the Vitalograph BreathCOa monitor (Model 29.700) assessed for alveolar
carbon monoxide ( COa) levels during deprivation conditions. To assess for compensatory cigarette smoking
during smokeless tobacco deprivation, a COa less than
8 ppm was defined as not using cigarettes.
Non-nicotinic replacement products. Two commercial
non-nicotinic products were used in this study: BACCOFF™ and DIPSTOP™ ( Ralston Inc., Selma, AL).
Research has shown that BACCOFF™ produces sensory
cues similar to common brands of moist snuff ( Coffey &
Lombardo, 1998). BACCOFF™ consists of a variety of
tea leaves, USP glycerine, sugar, salt, natural and
artificial flavors, and sodium benzoate. The primary
ingredient of the DIPSTOP™ liquid drops was lobeline,
an alkaloid shown to mimic peripheral nicotinic effects
in human and animal studies ( Stolerman, 1990). As a
control for the DIPSTOP™ condition, water was placed
in empty DIPSTOP™ liquid drop containers.
Nicotine dependence. The SMTDQ ( Boyle, Jensen,
Hatsukami, & Severson, 1995) is a 10-item self-report
measure designed to assess aspects of smokeless tobacco
use, which correspond with dependence. Scores range
from 4 to 19, with higher scores indicating greater levels
of smokeless tobacco dependence. Boyle et al. (1995)
showed a strong correlation between SMTDQ scores and
salivary cotinine ( r = 0.47, p<0.0001 ).
Nicotine withdrawal. The Minnesota Nicotine Withdrawal Scale (MNWS) assesses nicotine withdrawal
symptoms from cigarettes ( e.g., Hughes & Hatsukami,
1986 ) and smokeless tobacco (Hatsukami et al., 1987;
1992 ). The MNWS has good construct validity and high
reliability ( Patten & Martin, 1996). Individual items
include craving, irritability– anger, insomnia, anxiety–
tension, concentration problems, restlessness, drowsiness, impatience, increased appetite, and depressed
mood. Smokeless tobacco craving was derived from the
‘craving’ item on the MNWS. Total withdrawal represented the aggregate score of all items on the MNWS,
minus craving.
Smokeless tobacco approximation scale ( SMTAS). This
scale was developed specifically for the present study
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and assesses participants’ reports of how closely the nonnicotine substitutes approximated their original moist
snuff product. The smokeless tobacco approximation
scale consists of 11 Likert-format items that range from
1 ( not at all similar) to 10 ( extremely similar). Specific
items inquire whether the participant perceives the nonnicotine substitute to taste, feel, produce saliva, smell,
pack within mouth, arouse, produce a buzz, affect his
performance on tasks or exercise, relax, curb appetite, or
affect his concentration similar to his preferred moist
snuff. Within the present study, a coefficient alpha of
0.86 was produced by the data.
Procedure
Baseline assessment. Informed consent was obtained
from participants, and the SMTDQ was administered
during the initial baseline assessment period. Participants
were instructed to use their preferred moist snuff for
10 min. Following the using period, individuals were
instructed to expectorate into a test tube. Carbon
monoxide measures were obtained, and the MNWS was
administered. Individuals were then instructed to abstain
from any form of nicotine use for 2 days and to return the
following day. Participants were given the products
predetermined for that week and were instructed to use
those products ad lib for the 2-day abstinence period.
Graduate research assistants also informed participants
‘the products may or may not help during abstinence.’
Twenty-four-hour assessment. A graduate research assistant recorded the number of times individuals used the
product and inquired on the participant’s ability to
abstain. Saliva and COa measures were collected. The
MNWS self-report measure was also administered.
Participants were instructed to continue abstinence and
use the supplied products for another 24 h.
Forty-eight-hour assessment. Participants followed the
same procedure as the 24-h assessment period. After the
last self-report measures ( MNWS and SMTAS) were
taken, any remaining products were given to the graduate
researcher. Participants were asked to return to their
regular nicotine use until the beginning of the next
assessment week.
Results
Design and statistical approach
A within-subject 2´ 2´ 3 factorial design reflects three
independent within-subject variables: BACCOFF™
( BACCOFF™ vs. No BACCOFF™), DIPSTOP™ ( DIPSTOP™ vs. water), and time ( 0, 24 or 48 h). One-tailed
repeated-measure analyses of variances ( ANOVAs) were
conducted on each of the dependent variables. The
ANOVAs analyzed main effects for the independent
variables of BACCOFF™, DIPSTOP™, and time.
Interaction effects were also tested across the three
independent variables, which produced four different
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Table 1. The relationship between use patterns of non-nicotinic replacements with smokeless tobacco craving and nicotine withdrawal
symptoms
Product use
BACCOFF
DIPSTOP
WATER

24-h Craving

48-h Craving

24-h Withdrawal

48-h Withdrawal

–0.55*
0.08
0.21

–0.49
0.05
0.05

–0.07
0.00
–0.43

–0.08
–0.27
–0.48

* p<0.05.

comparisons. The interaction comparisons included
BACCOFF™ vs. DIPSTOP™, BACCOFF™ vs. time,
DIPSTOP™ vs. time, and BACCOFF™ vs. DIPSTOP™
vs. time. Post-hoc simple effect tests were used to
differentiate significant interactions. Significant differences within the simple effects were followed up with
Tukey Honestly Significant Differences tests at the 0.05
alpha level. Order effects were also tested using
3 ( time)´ 4 (order ) ANOVAs. Order of product administration was not shown to influence dependent measures.
Descriptive carbon monoxide levels and product
frequency data
All participants indicated full compliance. COa measures
demonstrated that participants were within the cut-off of
8 ppm during deprivation periods. Participants also
reported adequate BACCOFF™, DIPSTOP™, and placebo self-administration during deprivation. The mean
number and standard deviations of product self-administration at 24- and 48-h deprivation were as follows:
BACCOFF™ averaged 4.4±2.5 and 5.4±2.3, DIPSTOP™ averages were 3.0±0.7 and 3.5±1.0, and means
for water drops were 2.9±1.0 and 3.6±1.0, respectively.
Participants who reported self-administrating greater
amounts of BACCOFF™ at 24 h of nicotine deprivation
had significantly lower ratings of craving for smokeless
tobacco at the same time-point ( see Table 1). There were
no other significant relationships found comparing
product use with changes in craving and withdrawal
across time.
Non-nicotinic product influence on withdrawal and
craving scores
Significant time-main effects were observed for the total
withdrawal (F[2,30] = 4.40, p<0.01), craving ( F[2,30] =
7.17, p<0.001 ), and irritability scores ( F[2,30] = 6.19,
p<0.006). A BACCOFF™ main effect ( F[1,15] = 4.94,
p<0.05) was shown for the drowsiness score, and a
DIPSTOP™ main effect ( F[1,15] = 4.75, p<0.05) was
shown for the difficulty-concentrating score. Post-hoc
tests ( Tukey’s HSD) indicated that total withdrawal,
craving, and irritability were significantly greater at 24
and 48 h, compared to baseline, for each measure. In
addition, participants reported significantly lower problems with concentration when DIPSTOP™ was present
and lower drowsiness when BACCOFF™ was present.

Significant
interactions
were
observed
for
BACCOFF™ ´ time as a function of changes in total
withdrawal ( F[2,30] = 2.54, p<0.05), restlessness
( F[2,30] = 4.49, p<0.05), and appetite scores ( F[2,30] =
6.00, p<0.01). To illustrate the interaction effects, Figure
1 presents the overall interaction of total withdrawal.
Simple effects tests indicated that total withdrawal,
appetite, and restlessness scores were not substantially
different at the three time periods when BACCOFF™
was present ( F[2,30] = 1.55, 0.06, and 0.92, NS).
However, there were significant increases in total
withdrawal and appetite when BACCOFF™ was not
present ( F[2,30] = 10.93 and 10.48, p<0.01), with a
similar trend for restlessness ( F [2,30] = 2.23, p<0.06).
Post-hoc comparisons indicated that total withdrawal and
appetite scores were significantly higher at 24- and 48-h
deprivation, compared to baseline, when BACCOFF™
was not present. However, the interaction for restlessness
scores was seen only when comparing such scores at 48 h
between BACCOFF™ and no BACCOFF™ conditions.
Restlessness scores were significantly higher when
BACCOFF™ was not present compared with when it
was present ( t[15] = 2.6, p<0.02).
Non-nicotinic replacement approximation to moist
snuff
Scores on the SMT approximation questionnaire were
tabulated at the end of each 48-h assessment period in
order to evaluate which products participants reported as
most similar to their preferred most snuff. Two-tailed
t-tests were conducted on SMT approximation scores
among BACCOFF™, DIPSTOP™, and water condi-

Figure 1. Mean total withdrawal ratings for BACCOFF™ vs. No
BACCOFF™ differences across time. Significantly elevated total
withdrawal was noted in the No BACCOFF™ treatment.

NICOTINE & TOBACCO RESEARCH

tions. Results showed that BACCOFF™ ( mean±SD =
46.38±14.76) approximated participants’ preferred moist
snuff product more closely than DIPSTOP™ (32.91±8.8)
and water (17.84±6.93 ) conditions, t( 15) = 4.08 and 8.21,
p<0.001. Likewise, DIPSTOP™ was substantially more
similar to moist snuff than water, t( 15) = 2.46, p<0.05.
Discussion
The results of the study showed that a non-nicotinic
herbal product effectively reduced withdrawal symptoms
among individuals dependent on smokeless tobacco.
These observed herbal effects support the concept that
psychological factors (e.g., conditioned stimuli) influence signs and symptoms elicited during nicotine
deprivation. Researchers have historically posited that
the primary determinant of withdrawal symptoms was
the physiological removal of nicotine from the system
( Hatsukami, Hughes, & Pickens, 1985; Shiffman, 1979).
Our data, however, demonstrate that approximating
similar sensory features of smokeless tobacco behavior
substantially buffers certain aversive effects believed to
derive from nicotine’s removal.
Of particular interest was the finding that BACCOFF™ administration was reported to be the closest
approximation to participants’ preferred moist snuff. The
extent to which BACCOFF™ also produced a withdrawal-specific buffering effect across time implicates
the importance of using behavioral/sensory substitutes
within smokeless tobacco treatment that are of a similar
taste, feeling, packing-consistency, and smell ( to name a
few) as moist snuff. Although previous treatment studies
have employed similar mint snuff products and produced
conflicting results (Hatsukami et al., 2000; Stevens et al.,
1995; Zavala et al., 1995 ), an assessment of the
substitute’s approximation effect may help clarify the
mixed results.
Our findings also support recent studies conducted in
our laboratory examining the potential usefulness of
alternative sensory substitutes. For example, recent
studies have investigated the influence of chewing gum
on smoking behavior as well as on nicotine withdrawal
and craving ( Cohen, Britt, Collins, al’Absi, & McChargue, 2001; Cohen, Britt, Collins, Stott, & Carter, 1999;
Cohen, Collins, & Britt, 1997). Overall, studies conducting in our laboratory show that chewing gum helps with
withdrawal when cigarette smokers could not smoke.
The present data show comparable withdrawal effects
during short-term smokeless tobacco deprivation. However, nicotine-free substitutes in the present study did not
affect craving with smokeless tobacco users, whereas, in
previous studies, craving was reduced when smokers
were given chewing gum in some cases ( Cohen et al.,
1997 ), but not all ( Cohen et al., 2001 ). One explanation
for this inconsistent finding is that craving is multidimensional, comprised of appetitive and withdrawal
components ( Rohsenow, Niaura, Childress, Abrams, &
Monti, 1990–1991). It is possible that the BACCOFF™
acted as a conditioned stimulus eliciting an appetitive

199

craving response, while deprivation without the
BACCOFF™ elicited withdrawal-based craving of a
similar intensity level. This would have negated any
possible differences in craving during BACCOFF™
administration. It is not apparent that chewing gum
would have produced analogous effects because of its
dissimilarity to cigarettes.
The DIPSTOP™ (liquid lobeline) component neither
influenced craving nor nicotine withdrawal across 48 h
of deprivation. There are a couple of feasible interpretations of the ineffectiveness of lobeline to influence
craving and withdrawal symptoms. First, similar to
cigarette withdrawal, lobeline may not be effective in
assuaging the aversive qualities associated with smokeless tobacco deprivation. In fact, many researchers
believe that agents that approximate nicotinic effects on
the central nervous system (CNS) may be more important in the reduction of nicotine withdrawal and craving
during abstinence ( e.g., Picciotto, 1998). Because lobeline produces, to some extent, peripheral stimulant
effects similar to nicotine, the lack of CNS activation
may contribute to lobeline’s inability to buffer smokeless
tobacco withdrawal. Second, our study allowed smokeless tobacco users to self-administer the lobeline product
ad lib during deprivation. Although such a procedure is
consistent with smokeless tobacco cessation programs,
ad lib usage prevented the present study from standardizing the administered dose. Thus, it remains unclear
whether a controlled dose-specific administration might
have produced the desired effects in our laboratory
study.
Elevated withdrawal during the placebo condition
appeared to be comparable to 48-h smokeless tobacco
deprivation effects in a previous study (McChargue &
Collins, 1998). These findings suggest that smokeless
tobacco withdrawal produces reliable effects within our
deprivation challenge protocol. Although the present
study reports withdrawal severity that are lower than the
Hatsukami et al. study ( 1987 ), they were analogous to
the McChargue and Collins study examining smokeless
tobacco withdrawal using a similar methodology and
dependent undergraduate population. It is suggested that
the generalization of our findings to the population of
smokeless tobacco users may be limited. Our sample
consisted of young adults who reported low dependence
ratings ( mean = 7.8) on the smokeless tobacco dependence questionnaire. It remains unclear whether more
dependent smokeless tobacco users may respond as
favorably to the sensory substitute provided in the
present study.
A final limitation of this study reflects the lack of
biochemically verified abstinence. Although a biochemical assessment would have increased our confidence in the data, we employed a bogus pipeline to
increase the probability of more accurate self-reported
abstinence. As with other studies exploring cessation or
deprivation effects of tobacco users that also employed a
bogus pipeline ( Hansen et al., 1985; Murray et al.,
1987 ), post-study debriefing questions suggested that our
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participants did not misrepresent their abstinence reports.
Additionally, carbon monoxide levels suggested that
participants did not substitute smokeless tobacco with
cigarettes during the forced deprivation.
In conclusion, research examining smokeless tobacco
cessation appears to be sound but has not been well
evaluated. The few studies that have implemented
behavioral/sensory adjunctive components within
smokeless tobacco treatment protocols have reported
minimal effects. The present study documented effective
reductions in withdrawal as a function of an herbal
behavioral/sensory substitute within a laboratory setting,
with such reductions possibly tied to how similar the
substitute approximated moist snuff. These results exemplify the need for further work investigating behavioral/
sensory components that may contribute to the treatment
of smokeless tobacco users.
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